Quince Therapeutics (QNCX)Director sold ~$174K

~$174K

Approx. value · 50K sh @ $3.47

39K

Holds after · shares reported

Traded

Dec 26, 2025

Filed

Dec 30, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 12, 2025Company filing · Form 8-K · ResultsReported its results
2. Dec 26, 2025 · this disclosureInsiderDirector sold ~$174K of QNCX shares in the open market

What came next

1. Jan 30, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On January 30, 2026, each of Rajiv Patni, Luca Benatti, Margi McLoughlin, Una Ryan, and June Bray tendered his or her resignation as a member of the Board of Directors of Quince Therapeutics, Inc. (the “Company”), effective as of January 30, 2026.”
2. Feb 12, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
3. Mar 16, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On March 16, 2026, Quince Therapeutics, Inc. (the “Company”) received a notice (the “Bid Price Notice”) from the Nasdaq Listing Qualifications department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the closing bid price of the Company’s common stock for the last 30 consecutive business days had closed below the minimum $1.00 per share required for continued listing under Listing Rule…”
4. Mar 27, 2026Company filing · Form 8-K · Agreement ended, Reg FDEnded an important agreement, and shared information with investors
5. Apr 9, 2026Company filing · Form 8-K · Shareholder rights, Bylaws or charterChanged the rights of its shareholders, and changed its bylaws, charter or fiscal year
6. Apr 22, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On April 22, 2026, the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”) increased the number of directors on the Board to four and appointed June Bray as a Class I director of the Company to fill the resulting vacancy, effective immediately, to serve until the 2026 Annual Meeting of Stockholders, or until her earlier death, disqualification, resignation or removal.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Quince Therapeutics

OQRO holds no insider, Congress, fund or contract record for Quince Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its QNCX page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans